Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.90 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.23NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.30NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.1.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.87NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.33NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.46NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.58 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.21NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.31NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CP.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBGNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.98 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.32NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.1.13NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EF.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XPNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
DN.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BE.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.1.1.15NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BF.7.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CQ.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EC.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.2.52NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.243NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
R.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.216NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.16NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.420NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
L.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.518NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.551NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.207NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.604NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.111NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.619NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.36.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
C.36.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
A.23.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.316NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AZ.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.436NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.558NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.518NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.368NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used